# SirolimusEFR (sirolimus) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/sirolimus

> The FDA approved SirolimusEFR (sirolimus), sponsored by IRulya Therapeutics Inc. (IRLA), on September 30, 2024.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, quarter only, year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### Is SirolimusEFR (sirolimus) FDA approved?

Yes. The FDA approved SirolimusEFR (sirolimus), sponsored by IRulya Therapeutics Inc. (IRLA), on September 30, 2024. Press release filed with the SEC (EX-99): "FYARRO is approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (PEComa), with cumulative revenue of $25.2 million reported over the prior four quarters ended September 30, 2024." [Calendar and source filings](https://sec-api.dev/pdufa/sirolimus)

Source: Press release filed with the SEC (EX-99), accession 0001193125-24-282407, https://www.sec.gov/Archives/edgar/data/1422142/000119312524282407/d891246dex991.htm (retrieved 2026-11-12). Last confirmed 2024-12-20. Cite: https://sec-api.dev/pdufa/sirolimus#answer

## Key facts

| Field | Value |
| --- | --- |
| Drug | SirolimusEFR (sirolimus) |
| Codes | LAM-001 |
| Sponsor | IRulya Therapeutics Inc. (IRLA) https://sec-api.dev/companies/irla/catalysts |
| Indications | [pulmonary hypertension associated with interstitial lung disease](https://sec-api.dev/indications/pulmonary-hypertension-associated-with-interstitial-lung-disease) |
| Modality |  |
| FDA designations | breakthrough, fast track, orphan |

## Timeline

### September 30, 2024: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2024-12-20, last confirmed 2024-12-20.
- Press release filed with the SEC (EX-99) (accession 0001193125-24-282407): "FYARRO is approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (PEComa), with cumulative revenue of $25.2 million reported over the prior four quarters ended September 30, 2024." https://www.sec.gov/Archives/edgar/data/1422142/000119312524282407/d891246dex991.htm

### Q4 2026: trial start

- Status: scheduled. Date confidence: quarter. Stage: 2.
- First seen 2026-05-18, last confirmed 2026-11-13.
- Press release filed with the SEC (EX-99) (accession 0001193125-26-460775): "Sarcoidosis Associated Pulmonary Hypertension (SAPH): The Company plans to initiate a Phase 2 study of LAM-001 in SAPH in the fourth quarter of 2026, with data anticipated in the fourth quarter of 2028." https://www.sec.gov/Archives/edgar/data/1662774/000119312526460775/d190919dex991.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-350568): "In late 2026, the company also plans to initiate a Phase 2 study of LAM-001 in sarcoidosis-associated pulmonary hypertension (SAPH), a severe complication of pulmonary sarcoidosis with no approved therapy, that affects an estimated ~60K patients in the U.S. and Europe." https://www.sec.gov/Archives/edgar/data/1662774/000119312526350568/d163839dex991.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-228133): "In late 2026, the company also plans to initiate a Phase 2 study of LAM-001 in sarcoidosis-associated pulmonary hypertension (SAPH), a severe complication of sarcoidosis with no approved therapy affecting an estimated ~60K patients in the U.S. and Europe." https://www.sec.gov/Archives/edgar/data/1662774/000119312526228133/d109149dex991.htm
- SEC Form 10-Q (accession 0001193125-26-460562): "In addition, we expect to initiate a Phase 2 trial to evaluate the use of LAM-001 as a treatment for SAPH in late 2026, with data expected in the fourth quarter of 2028." https://www.sec.gov/Archives/edgar/data/1662774/000119312526460562/irla-20260930.htm
- SEC Form 10-Q (accession 0001193125-26-460562): "We intend to initiate a Phase 2 clinical trial specifically to evaluate LAM-001 as a treatment for SAPH in late 2026; however, there can be no assurance that the results observed in this single patient will be replicated in a broader patient population." https://www.sec.gov/Archives/edgar/data/1662774/000119312526460562/irla-20260930.htm
- SEC Form 10-Q (accession 0001193125-26-352201): "In addition, we expect to initiate a Phase 2 trial to evaluate the use of LAM-001 as a treatment for sarcoidosis-associated pulmonary hypertension in late 2026, with data expected in the fourth quarter of 2028." https://www.sec.gov/Archives/edgar/data/1662774/000119312526352201/qncx-20260630.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-228133): "A Phase 2a study in PH patients has been completed, a Phase 2 clinical study in BOS patients is ongoing, a Phase 2b study in PH-ILD is anticipated to begin in mid-2026, and a Phase 2 study in SAPH is anticipated to begin in late-2026." https://www.sec.gov/Archives/edgar/data/1662774/000119312526228133/d109149dex991.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-460775): "The Company plans to initiate a Phase 2 study in SAPH in the fourth quarter of 2026, with data anticipated in the fourth quarter of 2028." https://www.sec.gov/Archives/edgar/data/1662774/000119312526460775/d190919dex991.htm

### 2027: topline data readout

- Status: scheduled. Date confidence: year. Stage: 2. Indication: pulmonary hypertension associated with interstitial lung disease.
- First seen 2026-08-14, last confirmed 2026-08-14.
- Press release filed with the SEC (EX-99) (accession 0001193125-26-350568): ""We are pleased to have initiated the Phase 2b trial of LAM-001 for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD), and look forward to releasing top line bronchiolitis obliterans syndrome post lung transplant (BOS) data in the first quarter of next year." https://www.sec.gov/Archives/edgar/data/1662774/000119312526350568/d163839dex991.htm

### Q1 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2.
- First seen 2026-05-18, last confirmed 2026-08-14.
- Press release filed with the SEC (EX-99) (accession 0001193125-26-228133): " Phase 2b trial in PH-ILD to initiate in mid-2026, with topline data anticipated in the first quarter of 2028" https://www.sec.gov/Archives/edgar/data/1662774/000119312526228133/d109149dex992.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-350568): "Topline data is anticipated in the first quarter of 2028." https://www.sec.gov/Archives/edgar/data/1662774/000119312526350568/d163839dex991.htm

## Same indication

- [INS1201](https://sec-api.dev/pdufa/ins1201) (INSM)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/sirolimus.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "SirolimusEFR (sirolimus) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/sirolimus

```bibtex
@misc{secapidev_pdufa_sirolimus_20261116,
  title        = {SirolimusEFR (sirolimus) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/sirolimus}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_sirolimus_20261116","title":"SirolimusEFR (sirolimus) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/sirolimus","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
